Affiliations: [a] Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA | [b] Department of Radiology, University of Rochester Medical Center, Rochester, NY, USA | [c] Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA | [d] Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
Note: [
1
] This article received a correction notice (Erratum) post publication with DOI: 10.3233/BD-229001, available at http://doi.org/10.3233/BD-229001.
Abstract: Inflammatory breast cancer (IBC) is a rare variety of breast cancer accounting for two percent of breast cancer diagnoses in the United States. It is characterized by peau d’orange, breast edema and erythema on physical examination and dermal lymphatic invasion by tumor emboli on histological examination. Micrometastases to lymphatics and bone marrow at the time of diagnosis and angiogenic properties of IBC explain the high propensity of this cancer to relapse and metastasize, its aggressiveness and poor prognosis. Preoperative sequential anthracycline and taxane (plus trastuzumab and pertuzumab if HER2-positive) based chemotherapy is the current standard of care for IBC. We herein report a case of stage IIIC triple-negative IBC treated with pembrolizumab plus chemotherapy based neoadjuvant therapy with a complete clinical and complete pathological response. This is the first case of triple-negative IBC treated with this regimen reported in the literature, thereby providing clinical data on the tolerability and efficacy of pembrolizumab plus chemotherapy based neoadjuvant regimen for the treatment of IBC.
Keywords: Breast cancer, inflammatory breast cancer, pembrolizumab
DOI: 10.3233/BD-210041
Journal: Breast Disease, vol. 41, no. 1, pp. 255-260, 2022
